A significant increase in levels of cluster of differentiation 8+ (CD8+) tumor-infiltrating lymphocytes and PD-1/PD-L1–positive immune cells in patient tumor samples was observed after xevinapant treatment and, in addition, changes in expression of genes related to NFκB signaling were identified [67]. This evidence concerns the gene CD8A and neoplasm.